Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for INOVIO PHARMACEUTICALS, INC. Common Stock, $0.001 par value (INO).
- Disclosed ownership: 2.4%.
- Date of event: 30 Sep 2025.
Deep Track Capital, LP - 30 Sep 2025 SCHEDULE 13G/A Report for INOVIO PHARMACEUTICALS, INC. Common Stock, $0.001 par value (INO)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- INO
- Shares outstanding
- 54,555,851 shares
- Disclosed Ownership
- 1,314,796 shares
- Ownership
- 2.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 08:15:56 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 2.4% ownership in INOVIO PHARMACEUTICALS, INC. Common Stock, $0.001 par value (INO) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 08:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 2.4% | 1,314,796 | 0 | 1,314,796 | David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 2.4% | 1,314,796 | 0 | 1,314,796 | David Kroin | David Kroin, Director | |
| David Kroin | 2.4% | 1,314,796 | 0 | 1,314,796 | David Kroin | David Kroin |